The state of vascular endothelium, clinical and metabolic features of patients with coronary heart disease combined with nonalcoholic fatty liver disease

Authors

  • N. S. Mykhailovska Zaporizhzhia State Medical University,
  • L. Ye. Miniailenko Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2310-1237.2017.1.97505

Keywords:

coronary artery disease, nonalcoholic fatty liver disease, vascular endothelium, carotid intima-media thickness, arginine

Abstract

Objective: to study changes in the vascular endothelium state in conjunction with clinical and metabolic features in CHD patients with the concomitant nonalcoholic fatty liver disease.

Methods: cross-cohort analytical study involved 86 patients, the primarily selected group consisted of 34 patients, mean age 60 (57.5; 66) with documented coronary artery disease, stable exertional angina of II-III functional class combined with NAFLD; comparison selected group: 32 patients, mean age 60.5 (51.5; 65.6) with coronary artery disease without NAFLD. The control selected group consisted of 20 healthy individuals.

Results: In patients with coronary artery disease and NAFLD compared with CHD patients without NAFLD was found significantly higher levels of ADMA by 21 % (p < 0.05), CRP by 1.63 times (p < 0.05), intima-media thickness by 14.28 % (p < 0.05). Using ROC-analysis established that levels of ADMA >0.74 mmol/l is the cutting point and has an optimal ratio of sensitivity (80 %) to the specificity (82.9 %) for the diagnosis of vascular remodeling in CHD patients with concomitant NAFLD. The presence of significant direct correlation relationship of ADMA with CRP, total cholesterol, glucose, body mass index, alkaline phosphatase, ALT and significant negative relation of ADMA with HDL were found.

Conclusions: In patients with coronary artery disease, combined with NAFLD structural and functional changes in vascular endothelium (increase in serum levels of ADMA, thickening of intima-media) are observed during activation of systemic inflammation (increased CRP concentration), which is associated with metabolic disorders and liver damage indicators. The value of ADMA in serum prevailing 0.74 mmol/l helps to diagnose structural and functional changes in vascular endothelium in patients with coronary artery disease, comorbid with NAFLD.

References

Syvolap, V. D., & Mykhailovska, N. S. (2011). Prohnozuvannia fatalnykh i nefatalnykh koronarnykh podii u khvorykh na Q-infarkt miokarda z metabolichnym syndromom [Prediction of fatal and non-fatal coronary events in patients with Q-myocardial infarction and metabolic syndrome]. Zaporozhye medical journal, 1, 26–29. [in Ukrainian].

Skybchuk, V. A., & Onyschuk, Yu. I. (2014). Nealkoholna zhyrova khvoroba pechinky: suchasni pidkhody do diahnostyky ta likuvannia [Nonalcoholic fatty liver disease: current approaches to diagnosis and treatment]. Mystetstvo likuvannia, 2, 6–9. [in Ukrainian].

Alam, S., Mustafa, G., Alam, M., & Ahmad, N. (2016). Insulin resistance in development and progression of the nonalcoholic fatty liver disease. World Journal of Gastrointestinal Pathophysiology, 7(2), 211. doi: 10.4291/wjgp.v7.i2.211.

Mykhailovska, N. S., Oliinyk, T. V., & Mykhailovskyi, Y. M. (2015). Kliniko-patohenetychna rol imunozapalnykh porushen ta endotelialnoi dysfunktsii u khvorykh na ishemichnu khvorobu sertsia, komorbidnu z hipotyreozom [Clinical and pathogenetic role of immunoinflammatory disorders and endothelial dysfunction in patients with ischemic heart disease comorbid with hypothyroidism (reference review).]. Bukovynskyi medychnyi visnyk, 1(73), 227–231. [in Ukrainian].

Pivtorak, K. V. (2015). Dysfunktsiia endoteliiu ta porushennia funktsii pechinky pry nealkoholnii zhyrovii khvorobi pechinky [Endot helial dysfunction and violations of liver funct ion in nonalcoholic fatt y liver disease]. Visnyk Vinnytskoho natsionalnoho medychnoho universytetu, 2, 545–549. [in Ukrainian].

Sibal, L., Agarwal, S. C., Home, P. D., & Boger, R. H. (2010). The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Current Cardiology Reviews, 6(2):82-90. doi: 10.2174/157340310791162659.

Ferrigno, A., Pasqua, L. G Di., Berardo, C., Richelmi, P., & Vairetti, M. (2015). The liver plays a central role in asymmetric dimethylarginine-mediated organ injury. World Journal of Gastroenterology, 21(17), 5131–5137. doi: 10.3748/wjg.v21.i17.5131.

Meinitzer, A., Seelhorst, U., Wellnitz, B., Halwachs-Baumann, G., Boehm, B., Winkelmann, B., & Marz, W. (2007). Asymmetrical Dimethylarginine Independently Predicts Total and Cardiovascular Mortality in Individuals with Angiographic Coronary Artery Disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clinical Chemistry, 53(2), 273–283. doi: 10.1373/clinchem.2006.076711.

Leong, T., Zylberstein, D., Graham, I., Lissner, L., Ward, D., Fogarty, J., Bengtsson, C., et al. (2008). Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(5), 961–967. doi: 10.1161/ATVBAHA.107.156596.

Schulze, F., Lenzen, H., Hanefeld, C., Bartling, A., Osterziel, K., Goudeva, L., et al. (2006). Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. American Heart Journal, 152(3), 493.e1–493.e8. doi: 10.1016/j.ahj.2006.06.005.

Vairappan, B. (2015). Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. World Journal of Hepatology, 7(3), 443. doi: 10.4254/wjh.v7.i3.443.

Mykhailovska, N. S., & Miniailenko, L. E. (2016). The peculiarities of adiponectin and resistin interrelationships with the components of metabolic syndrome in patients with coronary heart disease and concomitant nonalcoholic fatty liver disease. Zaporozhye medical journal, 5(98), 25–30. doi: 10.14739/2310-1210.2016.5.82568.

Bueverov, A. O., & Bogomolov, O. N. (2009). Nealkogolʹnaya zhyrovaya boleznʹ pecheni: obosnovanie patogeneticheskoj terapii [Nonalcoholic fatty liver disease: a study of pathogenetic therapy]. Klinicheskie perspektivy gastrojenterologii, 1, 3–9. [in Russian].

Hughes, T., Althouse, A., Niemczyk, N., Hawkins, M., Kuipers, A., & Sutton-Tyrrell, K. (2012). Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial. Cardiovascular Diabetology, 11(1), 114. doi: 10.1186/1475-2840-11-114.

Dudinskaya, E. N., Tkacheva, O. N., Strazhesko, I. D., & Akasheva, D. U. (2013). Rol' insulinorezistentnosti i eyo korrekcii v processakh sosudistogo stareniya [Role of insulin resistance and its correction in the process of vascular aging]. Rational Pharmacotherapy in Cardiology, 9(2), 163–170. doi: http://dx.doi.org/10.20996/1819-6446-2013-9-2-163-170. [in Russian].

Gromnatska, N. M., Sklyarov, Ye. Ya., & Fomenko, I. S. (2014). Markery endotelialnoi dysfunktsii pry insulinorezystentnosti v ditei i pidlitkiv [Endothelial dysfunction markers in insulin resistance in children and adolescents]. Perinatologiya i pediatriya, 4, 72–76. [in Ukrainian]. doi10.15574/PP.2014.60.72.

Schekotova, A. P., Kotelnikova, L. P., Mugatarov, I. N., & Fedachuk, N. N. (2013). Eʹndotelial'naya disfunkciya, vospaleniye i fibroz pri gepatobilyarnoj patologii [Endothelial dysfunction, inflammation and fibrosis in the presence of hepatobiliary pathology]. Fundamental'nye issledovaniya, 5, 451–455. [in Russian].

Dynnyk, O. B., Stadnyuk, L. A., Mostovyi, S. E., & Myshanych, O. N. (2008). Pokaznyky dysfunktsii endoteliiu ta stan vnutrishnosertsevoi hemodynamiky u khvorykh z dyfuznymy zakhvoriuvanniamy pechinky [Indicators of the state of endothelial dysfunction and intracardiac hemodynamics in patients with the diffuse liver disease]. Ukrainskyi kardiolohichnyi zhurnal, 6, 66–74. [in Ukrainian].

Downloads

How to Cite

1.
Mykhailovska NS, Miniailenko LY. The state of vascular endothelium, clinical and metabolic features of patients with coronary heart disease combined with nonalcoholic fatty liver disease. Pathologia [Internet]. 2017Apr.7 [cited 2024Nov.2];(1). Available from: http://pat.zsmu.edu.ua/article/view/97505

Issue

No. 1 (2017)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).